Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
eFT508 · 1 trial · 1 indication
the proportion of subjects whose best overall response is a complete or partial response
| Arm | Type | Description |
|---|---|---|
| Part 1: eFT508 plus avelumab dose finding Arm | EXPERIMENTAL | subjects will receive eFT508 in combination with a fixed dose of avelumab |
| Part 2: eFT508 plus avelumab | EXPERIMENTAL | subjects will receive eFT508 in combination with a fixed dose of avelumab |
| Part 2: eFT508 alone | EXPERIMENTAL | subjects will receive eFT508 alone |
| Name | Type | Description |
|---|---|---|
| eFT508 | DRUG | eFT508 will be taken orally (PO) twice a day (bid). |
| Avelumab | DRUG | Avelumab 10 mg/kg will be administered intravenously (IV) on Day 1 and once every 2 weeks (q2wk) thereafter |
Inclusion Criteria: * ECOG performance status of 0, 1, or 2 * Pathologically documented diagnosis of colorectal adenocarcinoma. * Progressed on or intolerant of at least 2 prior cancer therapy regimens administered for metastatic disease. * Completion of all previous therapy (including surgery, rad...
eFT508 is an investigational small molecule being studied for the treatment of Microsatellite Stable Relapsed or Refractory Colorectal Cancer. It is a Phase 2 oncology drug that has been evaluated in a completed clinical trial. The drug is not approved and remains in clinical development.
eFT508 is a small molecule oncology drug. Its specific molecular target has not been disclosed in the available information. The drug is being studied for its potential effects in Microsatellite Stable Relapsed or Refractory Colorectal Cancer.
eFT508 is being developed by Merck & Company, Inc., which trades under the ticker MRK. The company is conducting clinical research on this investigational drug for the treatment of Microsatellite Stable Relapsed or Refractory Colorectal Cancer.
eFT508 is in Phase 2 clinical development. It is an investigational drug, not yet approved by regulatory authorities. A Phase 2 trial has been completed to evaluate its safety and efficacy in patients with Microsatellite Stable Relapsed or Refractory Colorectal Cancer.
eFT508 has been studied in one clinical trial, identified as NCT03258398. This Phase 2 study evaluated eFT508 alone and in combination with avelumab in subjects with Microsatellite Stable Colorectal Cancer. The trial was completed and enrolled 56 participants in the United States.
No, eFT508 is not the same as avelumab. eFT508 is an investigational small molecule being developed by Merck & Company, Inc. Avelumab is a separate drug that was studied in combination with eFT508 in a clinical trial for Microsatellite Stable Colorectal Cancer.